GLSI stock forecast, quote, news & analysis
Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences... Show more
Greenwich LifeSciences (GLSI) Stock Analysis: Clinical Momentum Meets a Consolidating Share Price
Key Takeaways
- GLSI shares have traded roughly flat over the last 30 days, easing about 2% from the mid-$16 level despite intraday swings between roughly $14 and $19.
- The stock remains below its 200-day moving average near $19.89 but has held near its 50-day moving average around $16.63.
- Investor attention centers on the Phase III FLAMINGO-01 trial of GLSI-100, the company's lead immunotherapy designed to prevent breast cancer recurrence.
- Analyst sentiment is mixed: HC Wainwright maintains a Buy with a $69 price target, while the broader consensus averages to a Hold and a third-party ratings firm downgraded the stock in late October.
- Greenwich LifeSciences is expected to report Q3 2026 results around November 13, 2026, with a consensus loss of $0.34 per share.
- For additional detail, explore the company's Price Targets, Earnings, and Forecast pages.
- You can also discover automated trading strategies and signals by exploring Trending AI Robots.
Current Market Snapshot
Greenwich LifeSciences has traded in a relatively narrow, consolidating range over the past month, holding near the $16–$17 level after a period of elevated volatility earlier in the year. With a market capitalization in the low-to-mid $200 million range and no reported revenue, the stock's valuation is driven almost entirely by clinical trial milestones and the perceived probability of future regulatory success rather than near-term fundamentals. Trading volume has been modest and below-average on several recent sessions, consistent with a clinical-stage biotech awaiting discrete news catalysts.
Greenwich LifeSciences (GLSI) Business Overview and Competitive Position
Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company headquartered in Stafford, Texas. Its lead product candidate, GLSI-100, combines the HER2-derived peptide GP2 with granulocyte-macrophage colony-stimulating factor (GM-CSF) as an immunotherapy designed to reduce the risk of breast cancer recurrence in patients who have completed standard treatment. The therapy is being evaluated in FLAMINGO-01, a global Phase III trial with Fast Track designation from the U.S. Food and Drug Administration.
Earlier Phase IIb data showed a reduction in recurrence rate of roughly 80% or greater over five years of follow-up in HER2/neu 3+ patients, positioning GLSI-100 as a potentially differentiated approach in a space where recurrence prevention remains a significant unmet need. The company is pre-revenue and relies on equity financing to fund its clinical program, making cash runway and enrollment progress central to the investment thesis.
Recent Developments Driving GLSI
Several developments have shaped GLSI's trading over the past 30 days. In late October, the company filed additional definitive proxy materials with the U.S. Securities and Exchange Commission and scheduled its annual stockholders' meeting for December 18, 2026. These corporate governance filings are routine but drew investor attention alongside a ratings action from Weiss Ratings, which downgraded the stock to a "Sell" designation on October 29, 2026.
On the analyst front, HC Wainwright has maintained a Buy rating with a $69 price target, reflecting a notably more constructive view than the overall consensus, which averages to a Hold. This divergence underscores the binary, milestone-driven nature of the stock. The company's most recent reported quarter, Q2 2026, came in ahead of expectations at a loss of $0.27 per share versus the $0.33 consensus estimate. Looking ahead, management's regulatory and manufacturing progress—including earlier FDA and European Medicines Agency approvals to use commercially manufactured GP2 in the trial—remains the primary fundamental backdrop.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-driven trading bots designed to identify and act on market patterns across thousands of tickers. While Tickeron offers hundreds of bots, only the top-performing and most relevant strategies are surfaced in this section. The bots vary widely in their approach, timeframe, and performance metrics, allowing users to compare automated strategies that suit different trading styles and risk tolerances. For those interested in supplementing their own research with systematic, data-driven signals, exploring this section can offer a practical way to observe how AI models approach both established names and more volatile, event-driven equities.
2026 Outlook and What Investors Should Watch
The primary driver of GLSI's investment story in 2026 is continued progress in the FLAMINGO-01 Phase III trial, including patient screening and enrollment, immune-response data, and any updated recurrence-rate observations from the open-label arm. Regulatory steps remain important as well: after securing FDA and EMA clearance to use commercially manufactured GP2, the company is pursuing similar approvals in the United Kingdom and Canada, with manufacturing scale-up and preparation for a potential Biologics License Application as longer-term goals.
Investors should also monitor the upcoming Q3 2026 earnings report, cash position and financing strategy, patent developments that could broaden the addressable market, and the insider lock-up period extended until January 31, 2027. As with any clinical-stage biotechnology company, the risk profile is elevated, and outcomes hinge on trial data, regulatory decisions, and the company's ability to maintain adequate funding.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
GLSI's Stochastic Oscillator dives into oversold zone
The Stochastic Oscillator for GLSI moved into oversold territory on November 13, 2026. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +12.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where GLSI advanced for three days, in 212 of 266 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 03, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on GLSI as a result. In 78 of 91 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 86%.
The Moving Average Convergence Divergence Histogram (MACD) for GLSI turned negative on November 05, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 35 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 83%.
GLSI moved below its 50-day moving average on November 02, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for GLSI crossed bearishly below the 50-day moving average on November 11, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 17 of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where GLSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 85%.
GLSI broke above its upper Bollinger Band on October 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for GLSI entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 55 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 55 (best 1 - 100 worst), indicating steady price growth. GLSI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 94 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: GLSI's P/B Ratio (71.438) is slightly higher than the industry average of (3.498). P/E Ratio (-9.541) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. GLSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry Biotechnology